Cellular Biomedicine will develop its stem cell and CAR-T projects exclusively in China , closing down its California operations. The company said a combination of lower costs for clinical trials and a faster path to commercialization prompted the turn toward China . News of the change in its business plan came as CBMG reported early signs of success in a China Phase I trial of AlloJoin™, its off-the-shelf mesenchymal progenitor cell therapy for Knee Osteoarthritis (KOA). CBMG has operations in Shanghai and Cupertino , California . More details.... Stock Symbol: (NSDQ: CBMG) Share this with colleagues: // //